Abstract: With the object of providing a novel anti-hallucination agent capable of suppressing, treating or preventing a hallucinatory symptom, the anti-hallucination agent of the invention contains an Atractylodes-derived crude drug as an active ingredient or contains a compound represented by the following formula (Ia), a stereoisomer thereof or a salt thereof as an active ingredient: in the formula, the double lines consisting of a solid line and a broken line represent a single bond or a double bond; R1 represents a hydrogen atom or a hydroxyl group, with the proviso that R1 does not exist when the carbon atom to which R1 is attached is linked to one of the neighboring carbon atoms through a double bond; R2 represents a hydrogen atom or is combined with R3 to represent a cyclic group which may have a substituent; and R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms which may have a substituent or is combined with R2 to represent a cyclic group which may have a substituent.

Abstract: A substance is disclosed that can inhibit the activity of aromatase (an enzyme capable of converting androgen into estrogen) to thereby effectively treat and/or prevent a sex hormone-dependent disease such as breast cancer occurring in a female person after menopause, as well as a climacteric disorder in a male person and metabolic syndrome caused by the accumulation of a visceral fat. Specifically, a therapeutic and/or prophylactic agent for a sex hormone-dependent disease comprises at least one herbal extract selected from the group consisting of “Kokeiten,” prunella spike, sweet hydrangea leaf, milk thistle, a jasmine tea, “Bokusoku,” “Tencha,” “Karensou,” “Youbaihi,” French maritime pine, betel palm, asparagus, “Rouro,” “Ryoukyou,” rooibos tea, rhubarb, pu-erh tea, green tea, “Ougon,” St.

Abstract: A substance is disclosed that can inhibit the activity of aromatase (an enzyme capable of converting androgen into estrogen) to thereby effectively treat and/or prevent a sex hormone-dependent disease such as breast cancer occurring in a female person after menopause, as well as a climacteric disorder in a male person and metabolic syndrome caused by the accumulation of a visceral fat. Specifically, a therapeutic and/or prophylactic agent for a sex hormone-dependent disease comprises at least one herbal extract selected from the group consisting of “Kokeiten,” prunella spike, sweet hydrangea leaf, milk thistle, a jasmine tea, “Bokusoku,” “Tencha,” “Karensou,” “Youbaihi,” French maritime pine, betel palm, asparagus, “Rouro,” “Ryoukyou,” rooibos tea, rhubarb, pu-erh tea, green tea, “Ougon,” St.

Abstract: Disclosed is a safe substance which can inhibit the activity of aromatase (an enzyme capable of converting androgen into estrogen) to thereby effectively treat and/or prevent a sex hormone-dependent disease such as breast cancer occurring in a female person after menopause, as well as a climacteric disorder in a male person and metabolic syndrome caused by the accumulation of a visceral fat. Specifically disclosed is a therapeutic and/or prophylactic agent for a sex hormone-dependent disease, which is characterized by comprising at least one herbal extract selected from the group consisting of “Kokeiten” (golden root), prunella spike, sweet hydrangea leaf, milk thistle, a jasmine tea, “Bokusoku” (a bark of Quercus acutissima or a closely related plant thereof), “Tencha” (sweet tea), “Karensou” (Eclipta prostrata), “Youbaihi” (a bark of Myrica rubra Sie b. et Zucc.), French maritime pine, betel palm, asparagus, “Rouro” (a root of Rhaponticum unifloru m DC.